IN2014MU00651A - Pharmaceutical compositions of sitagliptin - Google Patents

Pharmaceutical compositions of sitagliptin Download PDF

Info

Publication number
IN2014MU00651A
IN2014MU00651A IN651/MUM/2014A IN651MU2014A IN2014MU00651A IN 2014MU00651 A IN2014MU00651 A IN 2014MU00651A IN 651MU2014 A IN651MU2014 A IN 651MU2014A IN 2014MU00651 A IN2014MU00651 A IN 2014MU00651A
Authority
IN
India
Prior art keywords
pharmaceutical compositions
sitagliptin
processes
preparation
present invention
Prior art date
Application number
IN651/MUM/2014A
Inventor
Brij Khera
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Priority to IN651/MUM/2014A priority Critical patent/IN2014MU00651A/en
Priority to IN2014MU000000651 priority
Publication of IN2014MU00651A publication Critical patent/IN2014MU00651A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Abstract

The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.
IN651/MUM/2014A 2014-02-25 2014-02-25 Pharmaceutical compositions of sitagliptin IN2014MU00651A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN651/MUM/2014A IN2014MU00651A (en) 2014-02-25 2014-02-25 Pharmaceutical compositions of sitagliptin
IN2014MU000000651 2014-02-25

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN651/MUM/2014A IN2014MU00651A (en) 2014-02-25 2014-02-25 Pharmaceutical compositions of sitagliptin
PCT/IN2015/000104 WO2015128877A1 (en) 2014-02-25 2015-02-25 Pharmaceutical compositions of sitagliptin
US15/121,514 US20160367552A1 (en) 2014-02-25 2015-02-25 Pharmaceutical compositions of sitagliptin
PH12016501686A PH12016501686A1 (en) 2014-02-25 2016-08-25 Pharmaceutical compositions of sitagliptin
ZA2016/06075A ZA201606075B (en) 2014-02-25 2016-09-01 Pharmaceutical compositions of sitagliptin

Publications (1)

Publication Number Publication Date
IN2014MU00651A true IN2014MU00651A (en) 2015-10-23

Family

ID=53181316

Family Applications (1)

Application Number Title Priority Date Filing Date
IN651/MUM/2014A IN2014MU00651A (en) 2014-02-25 2014-02-25 Pharmaceutical compositions of sitagliptin

Country Status (5)

Country Link
US (1) US20160367552A1 (en)
IN (1) IN2014MU00651A (en)
PH (1) PH12016501686A1 (en)
WO (1) WO2015128877A1 (en)
ZA (1) ZA201606075B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019087054A1 (en) * 2017-11-01 2019-05-09 Zenvision Pharma Llp Novel pharmaceutical composition comprising dpp-4 inhibitor, alpha-lipoic acid and vitamin b12

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036114A1 (en) 2001-07-06 2004-08-11 Merck & Co Inc Tetrahydroimidazol [1,2-a] pyrazines and tetrahidrotriazol [4,3-a] pyrazines are as inhibitors of dipeptidyl peptidase useful for the treatment or prevention of diabetes
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
AU2004268024B2 (en) 2003-09-02 2007-07-12 Merck Sharp & Dohme Corp. Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20070021430A1 (en) 2003-09-23 2007-01-25 Chen Alex M Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005072530A1 (en) 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
EP1796671A4 (en) 2004-09-15 2009-01-21 Merck & Co Inc Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US20090221592A1 (en) 2005-07-25 2009-09-03 Ellison Martha E Dodecylsulfate Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
WO2007053904A1 (en) * 2005-11-10 2007-05-18 Alphapharm Pty Ltd Process to control particle size
DE602007003024D1 (en) 2006-06-27 2009-12-10 Sandoz Ag New method for salt production
US8334385B2 (en) 2007-11-02 2012-12-18 Glenmark Generics Limited Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof
WO2009085990A2 (en) 2007-12-20 2009-07-09 Dr. Reddy's Laboratories Limited Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
US20100041885A1 (en) 2008-03-25 2010-02-18 Nurit Perlman Crystalline forms of sitagliptin phosphate
US20090247532A1 (en) 2008-03-28 2009-10-01 Mae De Ltd. Crystalline polymorph of sitagliptin phosphate and its preparation
US8003672B2 (en) * 2008-04-21 2011-08-23 Merck Sharp & Dohme Corp. CB-1 receptor modulator formulations
PT2586782E (en) 2008-07-03 2015-02-03 Ratiopharm Gmbh Crystalline salts of sitagliptin
EP2324027B1 (en) 2008-07-29 2016-02-24 Medichem, S.A. New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
EP2331545B1 (en) 2008-08-27 2013-10-02 Cadila Healthcare Limited Improved process for preparation of (2r)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin- 7(8h)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine&new impurities in preparation thereof
WO2012131005A1 (en) * 2011-03-29 2012-10-04 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition of sitagliptin

Also Published As

Publication number Publication date
PH12016501686A1 (en) 2016-10-03
US20160367552A1 (en) 2016-12-22
WO2015128877A1 (en) 2015-09-03
ZA201606075B (en) 2017-08-30

Similar Documents

Publication Publication Date Title
SG11201606433PA (en) Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3322441A4 (en) Vaccine compositions
IL246978D0 (en) Novel pharmaceutical formulations
GB201402070D0 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
EP3096759A4 (en) Modified release formulations of pridopidine
WO2016011222A3 (en) Circular polynucleotides
EP3242672A4 (en) Amnion derived therapeutic composition and process of making same
IL250744D0 (en) Method of producing palbociclib and pharmaceutical compositions comprising the same
GB2536517B (en) Opthalmic drug compositions
EP3038465A4 (en) Oral pharmaceutical formulation of omarigliptin
GB201618482D0 (en) Pharmaceutical compositions
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
GB201409471D0 (en) Pharmaceutical composition
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
EP3102200A4 (en) Therapeutic compounds and compositions
WO2016011306A3 (en) Terminal modifications of polynucleotides
EP3171871A4 (en) Solid dosage form composition for buccal or sublingual administration of cannabinoids
IL251834D0 (en) Pharmaceutical compositions comprising peptide variants and methods of use thereof
IL261548D0 (en) 3-desoxy derivative and pharmaceutical compositions thereof
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
EP3347469A4 (en) Methods and compositions for the treatment of glaucoma
EP3096763A4 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
WO2015092810A3 (en) Amorphous form of idelalisib
WO2014144295A8 (en) Ceftolozane antibiotic compositions
EP3139909A4 (en) Topical formulation of hyperbranched polyglycerol-coated particles thereof